Prospective Validation of ATA Risk Score for Papillary Thyroid Microcarcinoma: An ITCO Real-World Study
The Journal of Clinical Endocrinology & Metabolism · 2025
DOI: 10.1210/clinem/dgaf190 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2025. Verfasst von Simone De Leo und 59 weiteren Autor:innen. Beteiligte Einrichtung: Endocrine Oncology Unit, Department of Endocrine and Metabolic Diseases, IRCCS Istituto Auxologico Italiano, Milan 20149, Italy. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Carcinoma, Papillary, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Ministry of Health to S.D.L., M.T. and L.F.
Abstract (Originalsprache)
Context
The risk of recurrence of papillary thyroid carcinoma (PTC) smaller than 1 cm (microPTC) is low. Predictors of disease persistence in microPTC are still unclear.
Objective
To compare the clinical and pathological characteristics of microPTCs with macrocarcinomas (PTC > 1 cm), identifying the predictors of biochemical and structural incomplete response 1 year after initial treatment in microPTC.
Methods
We included patients consecutively enrolled in the Italian Thyroid Cancer Observatory (NCT04031339), and selected patients with a histological diagnosis of PTC for whom complete pathological, clinical, treatment information, and results at the 1-year follow-up visits were available.
Results
Among 5038 patients in the cohort, 2345 (46.5%) had a microPTC. Patients with microPTCs had tumors with more indolent pathological features: only 3% of patients were classified as high risk according to the American Thyroid Association (ATA) risk stratification system for persistent or recurrent disease and 1% had distant metastases at diagnosis. MicroPTCs had a significantly better outcome: only 5% had a biochemical response and 2.3% a structural incomplete (SIR) response. Distant metastases at diagnosis were the best predictor of SIR in microPTCs (OR 5.13, 95% CI 1.11-23.73, P = .04). In a subgroup of 925 patients treated by total thyroidectomy and radioiodine treatment, the best predictor of SIR was the ATA high risk (OR 5.47, 95% CI 1.42-21.04, P = .01).
Conclusion
Our study confirms the favorable initial outcome of microPTC in a large series. We demonstrate that the ATA risk classification is reliable in predicting biochemical and structural persistence in patients with microPTC. Distant metastases, although rare, remain the best predictor of structural persistence at 1-year follow-up. These findings underscore the importance of tailored management strategies based on comprehensive risk stratification, rather than solely on tumor size.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Endocrine Oncology Unit, Department of Endocrine and Metabolic Diseases, IRCCS Istituto Auxologico Italiano, Milan 20149, Italy.
- Unit of Endocrinology, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena 41125, Italy.
- Department of Statistical Sciences, Sapienza University of Rome, Rome 00185, Italy.
- Operative Unit of Endocrinology Department of Medicine-DIMED University of Padua, Padua 35128, Italy.
- Department of Medicine and Surgery, University of Perugia, Perugia 06129, Italy.
- Oncological Endocrinology Unit, Department of Medical Sciences, Città della Salute e della Scienza Hospital, University of Turin, Turin 10126, Italy.
ORCID-Profile: Giulia Brigante, Bruno Madeo, Clotilde Sparano
Förderung
- Italian Ministry of Health to S.D.L., M.T. and L.F
Zitieren
APA
De Leo, S., Brigante, G., D'Elia, S., Censi, S., Madeo, B., Morelli, S., Nervo, A., Repaci, A., Sparano, C., Stramazzo, I., Virili, C., Bertagna, F., Dondi, F., Puxeddu, E., Talpacci, E., Zatelli, M. C., Ambrosio, M. R., Felicetti, F., Piovesan, A., …, & Alfo', M. (2025). Prospective Validation of ATA Risk Score for Papillary Thyroid Microcarcinoma: An ITCO Real-World Study. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgaf190
Vancouver
De Leo S, Brigante G, D'Elia S, Censi S, Madeo B, Morelli S, et al. Prospective Validation of ATA Risk Score for Papillary Thyroid Microcarcinoma: An ITCO Real-World Study. The Journal of Clinical Endocrinology & Metabolism. 2025. doi:10.1210/clinem/dgaf190
BibTeX
@article{DeLeo2025,
author = {De Leo, Simone and Brigante, Giulia and D'Elia, Silvia and Censi, Simona and Madeo, Bruno and Morelli, Silvia and Nervo, Alice and Repaci, Andrea and Sparano, Clotilde and Stramazzo, Ilaria and Virili, Camilla and Bertagna, Francesco and Dondi, Francesco and Puxeddu, Efisio and Talpacci, Edoardo and Zatelli, Maria Chiara and Ambrosio, Maria Rosaria and Felicetti, Francesco and Piovesan, Alessandro and Petrone, Luisa and Adornato, Virginia and Trevisan, Matteo and Fugazzola, Laura and Mele, Chiara and Zavattaro, Marco and Solaroli, Erica and Salituro, Nicola and Rossi, Mattia and Pagano, Loredana and Colapinto, Alessandra and Basso, Cristina and Ceresini, Graziano and Marina, Michela and Crocetti, Umberto and Massa, Michela and Deandrea, Maurilio and Retta, Francesca and Spiazzi, Giovanna and Rolli, Nicoletta and Bruno, Rocco and Carbone, Antonella and Rotondi, Mario and Magri, Flavia and Fallahi, Poupak and Chiofalo, Maria Grazia and Santaguida, Maria Giulia and Monti, Salvatore and Porcelli, Tommaso and Castello, Roberto and Sagnella, Alfonso and Clausi, Cristina and Di Dalmazi, Giulia and Tumino, Dario and Palermo, Andrea and Brunetti, Antonio and Lania, Andrea and Liverani, Andrea and Durante, Cosimo and Petrillo, Umberto Ferraro and Alfo', Marco},
title = {Prospective Validation of ATA Risk Score for Papillary Thyroid Microcarcinoma: An ITCO Real-World Study},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2025},
doi = {10.1210/clinem/dgaf190}
}
EUVIMED